Page 99 - TD-3-3

Tumor Discovery PTMAP5–hsa-miR-22-3p–KIF2C axis in HCC development

doi: 10.3390/cancers15051502 doi: 10.1186/s12935-019-0986-8
25. Li X, Huang W, Huang W, et al. Kinesin family members 36. Kang DH, Woo J, Kim H, et al. Prognostic relevance of
KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis HJURP expression in patients with surgically resected
and promote cell proliferation in hepatocellular carcinoma. colorectal cancer. Int J Mol Sci. 2020;21(21):7928.
Am J Transl Res. 2020;12(5):1614-1639. doi: 10.3390/ijms21217928
26. Shen T, Yang L, Zhang Z, et al. KIF20A affects the prognosis of 37. Sun X, Chen P, Chen X, et al. KIF4A enhanced cell
bladder cancer by promoting the proliferation and metastasis proliferation and migration via Hippo signaling and
of bladder cancer cells. Dis Markers. 2019;2019:4863182. predicted a poor prognosis in esophageal squamous cell
doi: 10.1155/2019/4863182 carcinoma. Thorac Cancer. 2021;12(4):512-524.
27. Keyhanian K, Lage JM, Chernetsova E, Sekhon H, doi: 10.1111/1759-7714.13787
Eslami Z, Islam S. Combination of MCM2 with Ki67 38. Wang D, Li Q, Li Y, Wang H. The role of MCM5 expression in
and p16 immunohistochemistry can distinguish uterine cervical cancer: Correlation with progression and prognosis.
leiomyosarcomas. Int J Gynecol Pathol. 2020;39(4):354-361. Biomed Pharmacother. 2018;98:165-172.
doi: 10.1097/PGP.0000000000000616 doi: 10.1016/j.biopha.2017.12.006
28. Liu Z, Li J, Chen J, et al. MCM family in HCC: MCM6 39. Gong C, Ai J, Fan Y, et al. NCAPG promotes the proliferation
indicates adverse tumor features and poor outcomes of hepatocellular carcinoma through PI3K/AKT signaling.
and promotes S/G2 cell cycle progression. BMC Cancer. Onco Targets Ther. 2019;12:8537-8552.
2018;18(1):200.
doi: 10.2147/OTT.S217916
doi: 10.1186/s12885-018-4056-8
40. Meng C, Zou Y, Hong W, Bao C, Jia X. Estrogen-regulated
29. Blackledge NP, Fursova NA, Kelley JR, Huseyin MK, PTTG1 promotes breast cancer progression by regulating
Feldmann A, Klose RJ. PRC1 catalytic activity is central to cyclin kinase expression. Mol Med. 2020;26(1):33.
polycomb system function. Mol Cell. 2020;77(4):857-874.e9.
doi: 10.1186/s10020-020-00161-7
doi: 10.1016/j.molcel.2019.12.001
41. Liu T, Zhang H, Yi S, Gu L, Zhou M. Mutual regulation of
30. Del Re M, Bertolini I, Crucitta S, et al. Overexpression of TK1 MDM4 and TOP2A in cancer cell proliferation. Mol Oncol.
and CDK9 in plasma-derived exosomes is associated with 2019;13(5):1047-1058.
clinical resistance to CDK4/6 inhibitors in metastatic breast
cancer patients. Breast Cancer Res Treat. 2019;178(1):57-62. doi: 10.1002/1878-0261.12457
doi: 10.1007/s10549-019-05365-y 42. Agarwal S, Behring M, Kim HG, et al. TRIP13 promotes
metastasis of colorectal cancer regardless of p53 and
31. Zhou F, Wang M, Aibaidula M, et al. TPX2 promotes microsatellite instability status. Mol Oncol. 2020;14(12):
metastasis and serves as a marker of poor prognosis in non- 3007-3029.
small cell lung cancer. Med Sci Monit. 2020;26:e925147.
doi: 10.1002/1878-0261.12821
doi: 10.12659/MSM.925147
43. Yin H, Wang X, Zhang X, et al. UBE2T promotes radiation
32. Li K, Zhang R, Wei M, et al. TROAP promotes breast resistance in non-small cell lung cancer via inducing
cancer proliferation and metastasis. Biomed Res Int. epithelial-mesenchymal transition and the ubiquitination-
2019;2019:6140951. mediated FOXO1 degradation. Cancer Lett. 2020;494:
doi: 10.1155/2019/6140951 121-131.

33. Wang-Bishop L, Chen Z, Gomaa A, et al. Inhibition of doi: 10.1016/j.canlet.2020.06.005
AURKA reduces proliferation and survival of gastrointestinal 44. Lou W, Liu J, Gao Y, et al. MicroRNA regulation of liver
cancer cells with activated KRAS by preventing activation of cancer stem cells. Am J Cancer Res. 2018;8(7):1126-1141.
RPS6KB1. Gastroenterology. 2019;156(3):662-675.e7.
45. Lou W, Liu J, Gao Y, et al. MicroRNAs in cancer metastasis
doi: 10.1053/j.gastro.2018.10.030 and angiogenesis. Oncotarget. 2017;8(70):115787-115802.
34. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting doi: 10.18632/oncotarget.23115
Cdc20 as a novel cancer therapeutic strategy. Pharmacol
Ther. 2015;151:141-151. 46. Cai G, Wu D, Wang Z, et al. Collapsin response mediator
protein-1 (CRMP1) acts as an invasion and metastasis
doi: 10.1016/j.pharmthera.2015.04.002 suppressor of prostate cancer via its suppression of
epithelial-mesenchymal transition and remodeling of actin
35. Sun J, Huang J, Lan J, et al. Overexpression of CENPF
correlates with poor prognosis and tumor bone metastasis cytoskeleton organization. Oncogene. 2017;36(4):546-558.
in breast cancer. Cancer Cell Int. 2019;19:264. doi: 10.1038/onc.2016.227

Volume 3 Issue 3 (2024) 23 doi: 10.36922/td.2846